Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats

International Journal of Pharmaceutics

Volumn 361, Issue 1-2, 2008, Pages 7-11

  Ujie, Kaori ^a   Oda, Masako ^a   Kobayashi, Michiya ^a   Saitoh, Hiroshi ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Fexofenadine; Intestinal absorption; Intestinal secretion; P Glycoprotein; Rats

Indexed keywords

CARRIER PROTEIN; CYCLOSPORIN A; FEXOFENADINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; KETOCONAZOLE; MITOXANTRONE; ORGANIC ANION TRANSPORTER; PROBENECID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SELECTIVITY; DUODENUM; ILEUM; INTESTINE ABSORPTION; INTESTINE MUCOSA; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROSA;

ANIMALS; BIOLOGICAL TRANSPORT; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PERMEABILITY; RATS; RATS, WISTAR; TERFENADINE;

EID: 47949102383     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.004     Document Type: Article

References (22)

1. Bailey D.G., Dresser G.K., Leake B.F., and Kim R.B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81 (2007) 495-502
2. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., and Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27 (1999) 866-871
3. Dietrich C.G., Geier A., and Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
4. Dresser G.K., Bailey D.G., Leake B.F., Schwarz U.I., Dawson P.A., Freeman D.J., and Kim R.B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71 (2002) 11-20
5. Englund G., Rorsman F., Ronnblom A., Karlbom U., Lazorova L., Grasjo J., Kindmark A., and Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29 (2006) 269-277
6. Ito K., Suzuki H., Horie T., and Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22 (2005) 1559-1577
7. Kageyama M., Namiki H., Fukushima H., Ito Y., Shibata N., and Takada K. In vivo effects of cyclosporine A and ketoconazole on the pharmacokinetics of representative substrate for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. Biol. Pharm. Bull. 28 (2005) 316-322
8. Kikuchi A., Nozawa T., Wakasawa T., Maeda T., and Tamai I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab. Pharmacokinet. 21 (2006) 308-314
9. Molimard M., Diquet B., and Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 18 (2004) 399-411
10. Naruhashi K., Tamai I., Inoue N., Muraoka H., Sai Y., Suzuki N., and Tsuji A. Involvement of mutidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob. Agents Chemother. 46 (2002) 344-349
11. Nozawa T., Imai K., Nezu J., Tsuji A., and Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308 (2004) 438-445
12. Perloff M.D., von Moltke L.L., and Greenblatt D.J. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J. Clin. Phrmacol. 42 (2002) 1269-1274
13. Petri N., Tannergren C., Rungstad D., and Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21 (2004) 1398-1404
14. Saitoh H., Fujisaki H., Aungst B.J., and Miyazaki K. Restricted intestinal absorption of some beta-lactam antibiotics by an energy-dependent efflux system in rat intestine. Pharm. Res. 14 (1997) 645-649
15. Saitoh H., Hatakeyama M., Eguchi O., Oda M., and Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87 (1998) 73-75
16. Shimizu M., Uno T., Sugawara K., and Tateishi T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br. J. Clin. Pharmacol. 61 (2006) 538-544
17. Simpson K., and Jarvis B. Fexofenadine. A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59 (2000) 301-321
18. Tahara H., Kusuhara H., Fuse E., and Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos. 33 (2005) 963-968
19. Takara K., Ohnishi N., Horibe S., and Yokohama T. Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. Drug Metab. Dispos. 31 (2003) 1235-1239
20. Tannergren C., Knutson T., Knutson L., and Lennernas H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55 (2003) 182-190
21. Tannergren C., Petri N., Knutson L., Hedeland M., Bondesson U., and Lennernas H. Multiple transport mechanism involved in the intestinal absorption and fires-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74 (2003) 423-436
22. Volk E.L., and Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 63 (2003) 5538-5543